Skip to Main Content
Services Talent Knowledge
Site Search


December 12, 2018

Barclay Damon Raises Over $100,000 for Tackle ALS; Media Attention for Tim Green and His Not-for-Profit Continues

Within two weeks of Tim Green, of counsel to the firm, launching his not-for-profit webpage Tackle ALS, firm attorneys and staff raised over $100,000 to support innovative ALS-treatment trials and to increase access to effective treatments for people living with ALS. The Team Barclay Damon fundraising page can be accessed here on any browser other than Internet Explorer.

Tackle ALS participants have collectively raised over $1.5 million in a month, prompting several large foundations to contribute an additional $7 million to the cause. Tackle ALS and the Healey Center for ALS at Massachusetts General Hospital now have enough funds to begin three drug trials, for which 1,000 ALS patients have already signed up.

Green's former Morning Edition producer Tom Goldman recently interviewed Green and his family and ALS doctor for an NPR profile discussing the disease, Tackle ALS, and Green's life as an NFL player and author.

Additionally, the firm's significant fundraising and visible support of Green resulted in a WSYR interview with Green's longtime friends and business partners John Langan, managing partner, and Rick Capozza, Energy Practice Area chair.

"Being able to rally around Tim has been encouraging and inspirational from our perspective," Langan said. "Right now, we're in a battle with him."


Click here to sign up for alerts, blog posts, and firm news.


Sign up to receive our latest news

Practice Areas

Featured Industries

New & Emerging Industry Practice Areas


Featured Media


NYS Courts to Implement Early Mandatory Mediation


Takeaways From the USDA Interim Final Rule on Domestic Hemp Production


The SHIELD Act: Update

This site uses cookies to give you the best experience possible on our site and in some cases direct advertisements to you based upon your use of our site.

By clicking [I agree], you are agreeing to our use of cookies. For information on what cookies we use and how to manage our use of cookies, please visit our Privacy Statement.

I AgreeOpt-Out